Alembic Pharmaceuticals Recalls Doxepin Hydrochloride Over Nitrosamine Impurity and CGMP Deviations
Alembic Pharmaceuticals Limited has initiated a Class II recall of 9,492 bottles of Doxepin Hydrochloride Capsules, USP, 10 mg, distributed nationwide in the USA. This voluntary action, effective July 25, 2025, stems from CGMP deviations involving a Nitrosamine Drug Substance Related Impurity exceeding proposed interim limits. This event underscores critical supply chain and regulatory risks for procurement and regulatory affairs teams managing generic antidepressant portfolios.
FDA-Initiated Class II Recall: Doxepin Hydrochloride Impacted by Nitrosamine Impurity and CGMP Deviations
Alembic Pharmaceuticals Limited has initiated a voluntary Class II recall, identified as D-0566-2025, for specific lots of its Doxepin Hydrochloride Capsules, USP, 10 mg. This critical action, commencing on July 25, 2025, impacts 9,492 bottles of the antidepressant, which were distributed nationwide across the USA. The primary driver for this recall is the detection of a Nitrosamine Drug Substance Related Impurity (NDSRI) at levels exceeding the proposed interim limit, a direct consequence of identified Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility. For procurement directors, this event necessitates an immediate review of Doxepin Hydrochloride inventory and supply contracts, particularly those tied to Alembic Pharmaceuticals Inc. as the marketer. The presence of NDSRIs, a class of genotoxic impurities, poses significant patient safety concerns and regulatory hurdles, demanding stringent quality control from all suppliers. Regulatory affairs heads must recognize that such CGMP deviations, even leading to a voluntary recall, signal a heightened risk profile for the manufacturing site and could trigger increased FDA scrutiny on future product submissions or facility inspections. This incident underscores the imperative for robust impurity profiling and adherence to evolving regulatory guidance on nitrosamine control, directly affecting product marketability and compliance.
Alembic Pharmaceuticals' Panchmahal Facility: Manufacturing Hub for US-Bound Doxepin Hydrochloride
The recalled Doxepin Hydrochloride Capsules, USP, 10 mg (ANDA215076), were manufactured by Alembic Pharmaceuticals Limited at its facility located in Village Panelav, P.O. Tajpura, Near Baska, Taluka Halol, Panchmahal, India. This site serves as a key production hub for generic pharmaceuticals destined for the US market, with the affected Doxepin Hydrochloride product specifically manufactured for Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA. The distribution pattern for the recalled product was nationwide in the USA, highlighting the broad market reach of this Indian manufacturing site. For supply chain VPs, this incident emphasizes the inherent risks associated with geographic concentration of manufacturing, particularly for critical generic drugs. A disruption at a single facility, such as the one in Panchmahal, can have cascading effects across the entire US supply chain for Doxepin Hydrochloride. Business development executives should note that manufacturing quality issues, even when addressed through a voluntary recall, can impact a company's reputation and its ability to secure new contracts or expand market share. Understanding the specific manufacturing origins and their compliance history is paramount for strategic sourcing and risk mitigation.
US Market Exposure: Supply Chain Vulnerability for Generic Doxepin Hydrochloride
The recall of 9,492 bottles of Doxepin Hydrochloride Capsules, USP, 10 mg, lot 2305015142, with an expiration date of September 30, 2025, represents a direct impact on the US pharmaceutical market. This product, identified by NDCs such as 62332-637-31, 62332-638-31, and others, is a human prescription drug administered orally, commonly used for its antidepressant properties. The nationwide distribution pattern means that pharmacies, wholesalers, and ultimately patients across the United States are affected by this supply disruption. Procurement directors must immediately assess their current inventory levels of Doxepin Hydrochloride and identify any exposure to the recalled lot. This event creates an immediate need to secure alternative supplies to prevent potential shortages and ensure continuity of patient care. For business development executives, this situation presents both a challenge and a potential opportunity; while the market experiences a disruption, companies with robust supply chains and compliant manufacturing can step in to fill the void. Regulatory affairs teams must also consider the implications for product labeling and post-market surveillance, as the presence of impurities necessitates a thorough review of product safety profiles and risk management plans.
Strategic Sourcing: Mitigating Doxepin Hydrochloride Supply Risk Without Named Alternatives
Given the recall of Alembic Pharmaceuticals' Doxepin Hydrochloride Capsules due to nitrosamine impurities and CGMP deviations, procurement teams face the immediate challenge of securing alternative sources. The current intelligence does not identify specific alternative suppliers for Doxepin Hydrochloride. This absence underscores the critical need for proactive supply chain diversification and rigorous supplier qualification processes. Procurement directors must initiate comprehensive searches for manufacturers capable of supplying Doxepin Hydrochloride, prioritizing those with robust quality systems and proven track records in nitrosamine risk management. The qualification timeline for a new pharmaceutical supplier can be extensive, often spanning months to years, involving facility audits, analytical testing, and regulatory submissions. Therefore, immediate action is paramount to minimize long-term supply disruptions. Supply chain VPs should consider geographic diversification to reduce reliance on single regions or facilities, thereby building resilience against similar future events. This incident serves as a stark reminder that the cost of qualifying multiple suppliers is often outweighed by the benefits of uninterrupted supply and reduced regulatory risk, especially for essential medications like Doxepin Hydrochloride.
Regulatory Scrutiny: Broader Compliance Implications for Alembic Pharmaceuticals and Indian Manufacturers
While this event is a voluntary, firm-initiated recall rather than an FDA Warning Letter, the underlying cause—CGMP deviations leading to nitrosamine impurities—carries significant regulatory implications for Alembic Pharmaceuticals Limited and, by extension, other manufacturers operating out of India. The FDA's Class II classification for this recall indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For regulatory affairs heads, this means that even a voluntary recall can trigger enhanced FDA oversight, including potential for future inspections of the Panchmahal facility. The broader regulatory environment is already characterized by heightened scrutiny, as evidenced by recent parallel events such as Essential Wellness Pharma's progesterone injection recall for sterility issues and an FDA hearing impacting Amgen's Tavneos market future. These incidents collectively signal a global regulatory landscape where compliance failures are met with swift and impactful actions. Business development executives should anticipate that this recall could affect Alembic's reputation and future market access, particularly for new product approvals, as regulators will scrutinize their quality systems more intensely. Proactive and transparent communication with regulatory bodies, coupled with demonstrable corrective actions, will be crucial for Alembic to mitigate long-term commercial repercussions.
Remediation and Future Outlook: Alembic's Path to Restoring Confidence and Supply Stability
Alembic Pharmaceuticals Limited's immediate priority following this recall must be a thorough investigation into the root cause of the CGMP deviations and the formation of the Nitrosamine Drug Substance Related Impurity in Doxepin Hydrochloride. This requires a robust corrective and preventive action (CAPA) plan, addressing not only the specific lot (2305015142) but also systemic issues across their manufacturing processes. For regulatory affairs teams, a comprehensive response to the FDA detailing these actions is paramount to demonstrate commitment to quality and patient safety. While no import alert has been issued, a failure to adequately address these fundamental CGMP issues could escalate regulatory actions in the future, potentially impacting all products from the Panchmahal facility destined for the US market. Supply chain VPs should monitor Alembic's remediation progress closely, as the long-term stability of Doxepin Hydrochloride supply depends on the effectiveness of these measures. Business development executives must understand that restoring market confidence will require not only technical remediation but also a clear communication strategy to reassure partners and customers of the company's commitment to quality. The industry's evolving understanding of nitrosamine risks means that continuous monitoring and adaptation of manufacturing processes will be an ongoing imperative for Alembic and all pharmaceutical manufacturers.